Do we need another NSAID instead of indomethacin for treatment of ductus arteriosus in preterm infants?

Acta Paediatrica, International Journal of Paediatrics

Volumn 92, Issue 9, 2003, Pages 996-999

  Leonhardt, A ^a   Seyberth, H W ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Ductus arteriosus; Indomethacin; Necrotizing enterocolitis; Non steroidal anti inflammatory drug; Preterm infants; Prostaglandins

Indexed keywords

DIGOXIN; DIURETIC AGENT; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

CLINICAL TRIAL; FEEDING; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE PERFORATION; KIDNEY FAILURE; NECROTIZING ENTEROCOLITIS; NEWBORN CARE; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENTERAL NUTRITION; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; MILK, HUMAN;

EID: 0141991092     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250310004973     Document Type: Review

References (36)

1. Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol 1973; 51: 220-5.
2. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976; 295: 526-9.
3. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976; 295: 530-3.
4. Fyler DC, Lang P. Neonatal heart disease. In: Avery GB, editor. Neonatology. Pathophysiology and management of the newborn. Philadephia: J. B. Lippincott Company; 1987.
5. Reilly PM, Wilkins KB, Fuh KC, Haglund U, Bulkley GB. The mesenteric hemodynamic response to circulatory shock: an overview. Shock 2001; 15: 329-43.
6. Greenough A, Milner AD, Dimitriou G. Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst Rev 2001; CD000456.
7. Edmonds JR, Berry E, Wyllie JH. Release of prostaglandins caused by distension of the lungs. Br J Surg 1969; 56: 622-623.
8. Clyman RI, Mauray F, Roman C, Rudolph AM, Heyman MA. Circulating prostaglandin E2 concentrations and patent ductus arteriosus in fetal and neonatal lambs. J Pediatr 1980; 97: 455-61.
9. Seyberth HW, Müller H, Wille L, Plückthun H, Wolf D, Ulmer HE. Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome. Pediatr Pharmacol (New York) 1982; 2: 127-41.
10. Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001; 6: 63-73.
11. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2002; 3: CD000174.
12. Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 1996; 128: 601-7.
13. Quinn D, Cooper B, Clyman RI. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics 2002; 110: e10.
14. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344: 1966-72.
15. Hwang H, Murphy JJ, Gow KW, Magee JF, Bekhit E, Jamieson D. Are localized intestinal perforations distinct from necrotizing enterocolitis? J Pediatr Surg 2003; 38: 763-7.
16. Vanhaesebrouck P, Thiery M, Leroy JG, Govaert P, de Praeter C, Coppens M, et al. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr 1988; 113: 738-43.
17. Raghuveer G, Speidel B, Marlow N, Porter H. Focal intestinal perforation in preterm infants is an emerging disease. Acta Pædiatr 1996; 85: 237-9.
18. Aschner JL, Deluga KS, Metlay LA, Emmens RW, Hendricks-Munoz KD. Spontaneous focal gastrointestinal perforation in very low birth weight infants. J Pediatr 1988; 113: 364-7.
19. Nagaraj HS, Sandhu AS, Cook LN, Buchino JJ, Groff DB. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg 1981; 16: 1003-7.
20. Buchheit JQ, Stewart DL. Clinical comparison of localized intestinal perforation and necrotizing enterocolitis in neonates. Pediatrics 1994; 93: 32-6.
21. Pumberger W, Mayr M, Kohlhauser C, Weninger M. Spontaneous localized intestinal perforation in very-low-birth-weight infants: a distinct clinical entity different from necrotizing enterocolitis. J Am Coll Surg 2002; 195: 796-803.
22. Novack CM, Waffarn F, Sills JH, Pousti TJ, Warden MJ, Cunningham MD. Focal intestinal perforation in the extremely-low-birth-weight infant. J Perinatol 1994; 14: 450-3.
23. Ojala R, Ikonen S, Tammela O. Perinatal indomethacin treatment and neonatal complications in preterm infants. Eur J Pediatr 2000; 159: 153-5.
24. Fujii AM, Brown E, Mirochnick M, O'Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol 2002; 22: 535-40.
25. Bellander M, Ley D, Polberger S, Hellstrm-Westas L. Tolerance to early human milk feeding is not compromised by indomethacin in preterm infants with persistent ductus arteriosus. Acta Pædiatr 2003; 92: 000-000.
26. Iwamoto HS. Endocrine regulation of the fetal circulation. In: Polin RA, Fox WW, editors. Fetal and neonatal physiology. Philadelphia: W. B. Saunders Company; 1998.
27. Norwood VF, Tufro-McReddie A, Gomez RA. Development of the renin-angiotensin system. In: Polin RA, Fox WW, editors. Fetal and neonatal physiology. Philadelphia: W. B. Saunders Company; 1998.
28. Robert A, Semble EL, Wu WC. Cytoprotection by prostaglandins. Scand J Gastroenterol 1981; Suppl 67: 223-7.
29. Seyberth HW, Rascher W, Hackenthal R, Wille L. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic ductus arteriosus. J Pediatr 1983; 103: 979-84.
30. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563-72.
31. Lopez R, Roig F, Llinas MT, Salazar FJ. Role of cyclooxygenase-2 in the control of renal haemodynamics and excretory function. Acta Physiol Scand 2003; 177: 429-35.
32. Brion LP, Campbell DE. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. Cochrane Database Systematic Reviews 2001: CD001148.
33. Leititis JU, Burghard R, Gordjani N, Wildberg A, Seyberth HW, Brandis M. Effect of a modified fluid therapy on renal function during indomethacin therapy for persistent ductus arteriosus. Acta Paediatr Scand 1987; 76: 789-94.
34. Scroop GC, Stankewytsch-Janusch B, Marker JD, Crofford LJ. Renin-angiotensin and autonomic mechanisms in cardiovascular homeostasis during haemorrhage in fetal and neonatal sheep. J Dev Physiol 1992; 18: 25-33.
35. Segar JL, Barna TJ, Acarregui MJ, Lamb FS, Crofford LJ. Responses of fetal ovine systemic and umbilical arteries to angiotensin II. Pediatr Res 2001; 49: 826-33.
36. Toda N, Ayaziki K, Okamura T, Crofford LJ. Modifications by endogenous prostaglandins of angiotensin II-induced contractions in dog and monkey cerebral and mesenteric arteries. J Pharmacol Exp Ther 1990; 252: 374-9.